Latest Breaking News On - Ndexxa azn gb0009895292 - Page 1 : comparemela.com

AstraZeneca to proceed with regulatory filings to convert from conditional to full approval in the US and EU ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa in. | June 5, 2023

United kingdomUnited statesPathw cardiolStuartj connollyJ vasc endovascColl cardiolAlexion pharmaceuticals incPopulation health research instituteHeart rhythm societyAmerican society of hematologyMcmaster universityCompany on twitter astrazenecaSafety monitoring boardSenior scientistHealth research instituteMaster university